While many investors are familiar with examples of smaller biotech firms delivering jaw-dropping intraday gains on the back of positive clinical trial news or FDA approvals,… Read More »This Biotech ETF’s Holdings “Are In A Sweet Spot For Takeover Activity”
The two biotech stocks highlighted in today’s article await big FDA decisions this month – one for an anti-itch drug that could be used in… Read More »Ahead Of Big FDA Decisions On Their Anti-Itch And Anti-Cancer Drugs, Analysts See These 2 Biotech Stocks As Solid Buys
Shares of the two drug makers discussed in today’s article have been beaten down, thanks in large part to an FDA advisory panel vote in… Read More »Are These 2 Beaten-Down Biotechs Buys Before Bouncing Back?
Looking at the biotech sector right now, new drug approvals could gain momentum in the wake of the FDA’s approval of Biogen’s Alzheimer’s drug, mergers… Read More »3 Outperforming Biotech Stocks With Further Upside In The Back Half Of 2021
“While the start of the calendar year is often prime time for U.S. Food and Drug Administration (FDA) events and trial data to be released,… Read More »With Major Catalysts This Summer, These 8 Biotech Stocks Could Heat Up
While the first coronavirus vaccine has received emergency use authorization from the FDA, the author of today’s article points out that “The coronavirus vaccine race… Read More »The Best Bets Right Now In The Ongoing COVID Vaccine Race For Aggressive – And Cautious – Investors
Investors looking for a post-election idea may want to consider the ETF highlighted in today’s article, which tracks an index “comprised of small- and mid-cap… Read More »Market History Suggests This “Breakthrough” ETF Is A Smart Post-Election Idea